Cure those hot flashes and more with our helpful menopause resources
NEW POSITION PAPER: Here Is the NAMS 2010 Position Paper on Estrogen and progestogen use in postmenopausal women. Click here to read the report in its entireity.
His and Her Health | Promote Your Page Too
| Article in Medical Journal Finds No Link in Estrogen Exposure and Heart Disease |
|
|
|
| Wednesday, 07 October 2009 | |
|
Dr. James A. Simon,
medical director of www.menopausewise.com wanted to be sure
his readers noted this press release and article. The press release is
from the Journal of Women's Health. At the end of the press release is a
link to the article.Here is the release:
New
Rochelle, NY, September 23, 2009—In
the ongoing controversy over the relationship between Estrogen and Heart Disease
risk, results from the WISE study reveal that the length of time women are
exposed to estrogen is not related to their risk for Coronary artery disease
(CAD) or a major cardiovascular event, except in the case of postmenopausal
hormone therapy, which appears to protect against CAD with extended use. A new
twist in the debate over HT and its role in preventing or slowing the
development of coronary artery disease suggests that a cardioprotective role for
estrogen cannot be determined
on
the basis of estrogen exposure time alone and is likely influenced by other
variables as well.
Led by C. Noel Bairey Merz, MD, from Cedars-Sinai Women’s Heart Center and the University of California School of Medicine, Los Angeles, a team of investigators from the University of Pittsburgh, University of Alabama, University of Florida, Rhode Island Hospital, and the National Heart, Lung, and Blood Institute (NHLBI) calculated the total estrogen exposure time (TET) for a group of 646 postmenopausal women who were being evaluated for symptoms suggestive of obstructive CAD. The researchers looked for a relationship between TET and evidence of CAD, as well as a major cardiovascular event such as heart attack or stroke. In the article “Total Estrogen Time and Obstructive Coronary Disease in Women: Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE),” the investigators present the following conclusions: Women with the longest duration of estrogen exposure had the lowest occurrence and severity of CAD; however, postmenopausal hormone therapy appears to be the reason for that association, and when the data are adjusted for HT use, there is no link between TET and CAD. Furthermore, TET is not related to the risk for a major cardiovascular event. “This important study helps to address the complexity of the hormone therapy controversy and adds to our growing understanding. The issue of timing in treatment with hormone therapy is clearly a factor that must be considered in weighing potential benefits and risks,” says Wendy S. Klein, MD, Deputy Editor of Journal of Women’s Health, and Associate Professor Emeritus at Virginia Commonwealth University, Richmond, VA. These findings are presented and analyzed in an article published in Journal of Women’s Health, a peer-reviewed journal published by Mary Ann Liebert, Inc. ( www.liebertpub.com). The article is available free online at www.liebertpub.com/jwh |
|
| Last Updated ( Wednesday, 07 October 2009 ) |